This site is intended only for healthcare professionals resident in Egypt

Search

Menu

Close

Sign InLog Out Our medicinesTherapy areasExplore contentExplore contentEventsDownloadable materialsVideosLet’s connectLet's ConnectContact usAsk a questionPfizer medical information
Lorbrena

Menu

Close

Unmet Need Molecular Structure Guidelines Study design Efficacy Safety Dosing and Therapy Management Summary Important Safety Information Abbreviated Prescribing Information
Guidelines

LORBRENA™ is recommended by international guidelines2


*The NCCN Guidelines™ for NSCLC provide recommendations for certain individual biomarkers that should be tested and recommend testing techniques but do not endorse any specific commercially available biomarker assays or commercial laboratories.
 

†See the NCCN Guidelines for detailed recommendations, including other preferred options.

 

Abbreviations: ALK, Anaplastic lymphoma kinase; CNS, Central nervous system; DoR, Duration of response; ESMO, European Society for Medical Oncology; NSCLC, Non-small cell lung cancer; ORR, Objective response rate; PFS, Progression-free survival; TKI, Tyrosine kinase inhibitor.

References:Lorbrena™ EDA leaflet approval date 26/4/2021.Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Non-Small Cell Lung Cancer V4.2021. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed May, 2021. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Available at: https://www.esmo.org/Guidelines/Lung-and-Chest-Tumours/Metastatic-Non-Sm...(link is external). Accessed May, 2021.

MOH Approval No: HF0098OA54/062022
Invalidation date: 12/06/2024

PP-LOR-EGY-0012

Adverse events should be reported. Adverse events can be reported to [email protected]

PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign inRegisterAccountSign Out

The product information provided in this site is intended only for Healthcare Professionals of Egypt. The products discussed herein may have different product labeling in different countries. 

 

Copyright © 2023 Pfizer biopharmaceutical LLC. All rights reserved.

 

PP-UNP-EGY-0064
For Egypt Healthcare Professionals

These pages are not intended for patients or members of the general public. This portal contains healthcare promotional content.
 If you select ""No"", you will be redirected to Pfizer.com, the global Pfoizer websitee.
 I confirm that i am a healthcare professional resident in Egypt.

Yes No
You are leaving the Pfizer for Professionals website
​
You are being directed to a third-party website:

This link is provided for your convenience. Please note that this third-party website is not controlled by Pfizer for Professionals or subject to our privacy policy.
 
PP-UNP-EGY-0064